Aptorum Group(NASDAQ) APM

Current Price$8.15

Market Cap$6.82M

Since IPO (2018)-99%

5 Year-97%

1 Year-52%

1 Month+3%

Aptorum Group last closing stock price
Metric	Price	Date
Last close	USD 8.38	2026-07-24

Aptorum Group stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+19.71%	USD 7.00	2026-07-17
1 month	+3.05%	USD 8.13	2026-06-24
3 month	-6.59%	USD 8.97	2026-04-24
Year to date	-20.94%	USD 10.60	2025-12-31
1 year	-52.11%	USD 17.50	2025-07-24
3 year	-58.51%	USD 20.20	2023-07-25
5 year	-96.83%	USD 264.00	2021-07-23
Since inception	-99.4%	USD 1,435.00	2018-12-18

Aptorum Group Financials at a Glance

Market Cap

$6.82M

Revenue (TTM)

$960.82K

Net Income (TTM)

-$10.66M

EPS (TTM)

-$3.52

P/E Ratio

-2.38

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Price

$8.15

Volume

1,532

Open

$8.60

Price

$8.15

Volume

1,532

Open

$8.60

Previous Close

$8.15

Daily Range

$7.81 - $8.60

52-Week Range

$6.00 - $44.70

Estimated Earnings Date

Jul 3, 2026

Dividend

$0.00

Beta (Volatility)

0.65 (Low)

Price

$8.15

Volume

1,532

Open

$8.60

Previous Close

$8.15

Daily Range

$7.81 - $8.60

52-Week Range

$6.00 - $44.70

Estimated Earnings Date

Jul 3, 2026

APM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aptorum Group

Aptorum Group Limited is a biopharmaceutical company focused on developing new therapies that address unmet medical needs. The company leverages advanced technology to explore innovative pathways in drug discovery and clinical development.

Products and Services

Novel therapies targeting infectious diseases

Drug development for metabolic disorders

Treatments for rare diseases

Research collaboration with leading institutions

What Makes Aptorum Group Limited Special

Aptorum Group Limited is distinguished by its strategic focus on unmet medical needs, enabling it to explore unique opportunities within the healthcare sector. The company combines scientific expertise with strong business acumen, enhanced by collaborations with top-tier research institutions and industry partners. This approach facilitates an innovative ecosystem geared toward optimizing drug discovery and creating sustainable growth.

Five Things You Need to Know

Aptorum Group targets infectious diseases, metabolic disorders, and rare conditions.

The company employs cutting-edge technology in its drug development processes.

Strong leadership capable of steering innovative scientific and business strategies.

Strategic partnerships enhance its research and development capabilities.

Aimed at delivering long-term shareholder value through a diversified pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Ian Huen, CFA

Website

www.aptorumgroup.com

Headquarters

London, GL W1S 1BN, GB

APM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-5.94%

Return on Capital

-6.84%

Return on Assets

-7.29%

Earnings Yield

-42.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.82M

Shares Outstanding

814.40K

Volume

1.53K

Avg. Volume

79.53K

Financials (TTM)

Gross Profit

$705.82K

Operating Income

-$10.63M

EBITDA

-$10.37M

Operating Cash Flow

-$8.97M

Capital Expenditure

-$3.02K

Free Cash Flow

-$8.97M

Cash & ST Invst.

$3.45M

Total Debt

$3.44M

Aptorum Group Performance Analysis

Aptorum Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,295,889	-15.9%
2023	2023-12-31	USD 431,378	-66.7%
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 0	N/A

Aptorum Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	N/A
Q4	2024-12-31	N/A
Q2	2025-06-30	N/A
Q4	2025-12-31	-100.0%

Aptorum Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -27.45	-61.6%
2023	2023-12-31	USD -6.25	-77.2%
2024	2024-12-31	USD -7.83	25.3%
2025	2025-12-31	USD -1.85	-76.3%

Aptorum Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	-198.0%
Q4	2024-12-31	42.0%
Q2	2025-06-30	78.6%
Q4	2025-12-31	-109.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$6.82M

N/A

Market Cap/Employee

$3.41M

N/A

Employees

N/A

Net Income

-$921.49K

-134.6%

EBITDA

-$1.41M

-151.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$3.45M

+72.2%

Total Debt

$3.44M

-1.3%

Accounts Receivable

$8.75K

-87.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.44M

+944.4%

Return on Assets

-7.29%

N/A

Return on Invested Capital

-2.86%

N/A

Free Cash Flow

$89.73K

+101.6%

Operating Cash Flow

$89.73K

+101.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IMRNImmuron Limited

IMRNImmuron Limited$1.11-5.13%

BOLTBolt Biotherapeutics, Inc.

BOLTBolt Biotherapeutics, Inc.$3.83+0.52%

CLRBCellectar Biosciences, Inc.

CLRBCellectar Biosciences, Inc.$2.41-2.43%

EVGNEvogene Ltd.

EVGNEvogene Ltd.$0.54-0.04%

COCPCocrystal Pharma, Inc.

COCPCocrystal Pharma, Inc.$0.90-2.17%

MBIOMustang Bio, Inc.

MBIOMustang Bio, Inc.$0.56-1.42%

LYRALyra Therapeutics, Inc.

LYRALyra Therapeutics, Inc.$0.52+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$92.32-0.08%

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

CLFCleveland-Cliffs

CLFCleveland-Cliffs$11.93+0.09%

Questions About APM

What is the current price of Aptorum Group?

Aptorum Group is trading at $8.15 per share.

What is the 52-week range for Aptorum Group?

Over the past 52 weeks, Aptorum Group has traded between $6.00 and $44.70.

How much debt does Aptorum Group have?

As of the most recent reporting period, Aptorum Group reported total debt of $3.52M.

How much cash does Aptorum Group have on hand?

Aptorum Group reported $3.45M in cash and cash equivalents in its most recent financial results.

What is Aptorum Group’s dividend yield?

Aptorum Group does not currently have a dividend yield.

Aptorum Group(NASDAQ) APM

Aptorum Group Financials at a Glance

APM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aptorum Group

Products and Services

What Makes Aptorum Group Limited Special

Five Things You Need to Know

APM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aptorum Group Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About APM

What is the current price of Aptorum Group?

What is the 52-week range for Aptorum Group?

How much debt does Aptorum Group have?

How much cash does Aptorum Group have on hand?

What is Aptorum Group’s dividend yield?

Premium Investing Services